Startup behind ‘radically’ cheap drugs to go public in $1.8B SPAC deal

Less than two years after emerging from stealth with one of the biotech industry’s largest-ever Series A rounds, EQRx is going public in a reverse merger with a special-purpose acquisition company, or SPAC, that values the startup at $1.8 billion.